Erratum: Cyclin D1 promotes anchorage-independent cell survival by inhibiting FOXO-mediated anoikis (Cell Death and Differentiation (2009) 16 (1408-1417) DOI: 10.1038/cdd.2009.86));Cyclin D1 promotes anchorage-independent cell survival by inhibiting FOXO-mediated anoikis

Cell Death and Differentiation

Volumn 16, Issue 10, 2009, Pages 1408-1417

  Gan, L ^a,b   Liu, P ^a,b   Chen, S ^a,b   Yang, J ^b   McCarthy, J B ^b   Knudsen, K E ^c   Huang, H ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1;

ANOIKIS; ARTICLE; CARCINOGENESIS; CELL SURVIVAL; CONTROLLED STUDY; GENE FUNCTION; GENE REPRESSION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; WILD TYPE;

EID: 70349185119     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2010.15     Document Type: Erratum

References (39)

1. Schwartz MA. Integrins, oncogenes, and anchorage independence. J Biol Chem 1997; 139: 575-578.
2. Frisch SM, Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol 1997; 9: 701-706.
3. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285: 1028-1032.
4. Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J et al Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003; 5: 733-740.
5. Mailleux AA, Overholtzer M, Schmelzle T, Bouillet P, Strasser A, Brugge JS. BIM regulates apoptosis during mammary ductal morphogenesis, and its absence reveals alternative cell death mechanisms. Dev Cell 2007; 12: 221-234.
6. Li Z, Zhao J, Du Y, Park HR, Sun SY, Bernal-Mizrachi L et al. Down-regulation of 14-3-3 zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci USA 2008; 105: 162-167.
7. Woods NT, Yamaguchi H, Lee FY, Bhalla KN, Wang HG. Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res 2007; 67: 10744-10752.
8. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005; 24: 7410-7425.
9. Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 2003; 162: 613-622.
10. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-868.
11. Modur V, Nagarajan R, Evers BM, Milbrandt J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 2002; 277: 47928-47937.
12. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci 2007; 120: 2479-2487.
13. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
14. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002; 297: 63-64.
15. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001; 411: 1017-1021.
16. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994; 369: 669-671.
17. Creighton CJ. Multiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumors. PLoS ONE 2008; 3 e1816.
18. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004; 18: 2699-2711.
19. Ewen ME, Lamb J. The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med 2004; 10: 158-162.
20. Huang H, Regan KM, Lou Z, Chen J, Tindall DJ. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 2006; 314: 294-297.
21. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-626.
22. Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 1999; 59: 4148-4154.
23. Weng Z, Xin M, Pablo L, Grueneberg D, Hagel M, Bain G et al. Protection against anoikis and down-regulation of cadherin expression by a regulatable beta-catenin protein. J Biol Chem 2002; 277: 18677-18686.
24. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006; 125: 665-677.
25. Liu P, Kao TP, Huang H. CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor. Oncogene 2008; 27: 4733-4744.
26. Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 2003; 114: 323-334.
27. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: Polymorphism, aberrant splicing and cancer risk. Oncogene 2006; 25: 1620-1628.
28. Radu A, Neubauer V, Akagi T, Hanafusa H, Georgescu MM. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol 2003; 23: 6139-6149.
29. Liu P, Li S, Gan L, Kao TP, Huang H. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. Cancer Res 2008; 68: 10290-10299.
30. Benzeno S, Lu F, Guo M, Barbash O, Zhang F, Herman JG et al. Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1. Oncogene 2006; 25: 6291-6303.
31. Gladden AB, Woolery R, Aggarwal P, Wasik MA, Diehl JA. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 2006; 25: 998-1007.
32. Lin DI, Lessie MD, Gladden AB, Bassing CH, Wagner KU, Diehl JA. Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis. Oncogene 2008; 27: 1231-1242.
33. Liotta LA, Kohn E. Anoikis: Cancer and the homeless cell. Nature 2004; 430: 973-974.
34. Aggarwal P, Lessie MD, Lin DI, Pontano L, Gladden AB, Nuskey B et al Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes Dev 2007; 21: 2908-2922.
35. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997; 11: 957-972.
36. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000; 6: 1891-1895.
37. Petre-Draviam CE, Williams EB, Burd CJ, Gladden A, Moghadam H, Meller J et al. A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene 2005; 24: 431-444.
38. Klier M, Anastasov N, Hermann A, Meindl T, Angermeier D, Raffeld M et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008; 22: 2097-2105.
39. Sauter D, Himmelsbach K, Kriegs M, Carvajal Yepes M, Hildt E. Localization determines function: N-terminally truncated NS5A fragments accumulate in the nucleus and impair HCV replication. J Hepatol 2009; 50: 861-871.